GlassScriptPhysician profile
Suzanne A Hoekstra
NPI 1508840216
$4,434.52
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,288 · 2020: $124 · 2021: $250 · 2022: $2,001 · 2023: $723 · 2024: $48.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $623 · Food and Beverage: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $623.11 |
| Food and Beverage | $148.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic INC | $2,190.22 | 2022-2023 | Biozorb, Localizer |
| Astrazeneca Pharmaceuticals LP | $678.93 | 2019-2024 | Tagrisso |
| Medtronic USA, INC. | $570.45 | 2019 | |
| Myriad Genetic Laboratories, INC. | $250.00 | 2021 | |
| Genentech USA, INC. | $191.82 | 2019 | |
| Stryker Corporation | $143.48 | 2022 | |
| Abbvie INC. | $139.87 | 2019 | |
| Merck Sharp & Dohme LLC | $79.61 | 2022 | |
| Kci USA, INC. | $73.06 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.09 | 2019 | |
| Eisai INC. | $31.28 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $19.05 | 2019 | |
| Puma Biotechnology, INC. | $17.63 | 2019 | |
| Celgene Corporation | $15.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Hoekstra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.